NeuroOne Medical restates Q2 product revenue to USD 1.86 million after ASC 606 error

NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation

NMTC

0.00
  • NeuroOne Medical Technologies filed restated results for the quarter ended March 31, 2026, correcting duplicated product revenue tied to modified purchase orders.
  • Restatement cut product revenue by USD 529,135 for the quarter, trimming product gross profit by USD 296,353.
  • Accounts receivable fell USD 529,135. Inventory rose USD 232,782. Total assets dropped USD 296,353.
  • Net loss widened to USD 2.38 million for the quarter. Six-month net loss widened to USD 3.82 million.
  • Cash was unchanged. Management cited a process control deficiency in purchase order tracking. Enhanced reconciliation controls are being implemented.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuroone Medical Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-068307), on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.